Efficacy of MahÄ?paiÅ?acika GhÅ?ta against KÅ«Å?maÅ?Ä?a GhÅ?ta in Attention - Deficit/Hyperactivity Disorder
Not Applicable
Not yet recruiting
- Conditions
- Health Condition 1: F902- Attention-deficit hyperactivity disorder, combined type
- Registration Number
- CTRI/2023/05/053180
- Lead Sponsor
- Shifa Aboobacker V
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
a)Participants satisfying the DSM 5 Diagnostic criteria for ADHD
b)Participants with age group 6-12 years
c)Participants fit for Å?amana SnehapÄ?na
d)No discrimination of sex, religion, caste and economic status
•Participants with due consent.
Exclusion Criteria
a)Intellectual Disability
b)Pervasive developmental disorder
c)Epilepsy and other neurological disorder
d)Participants undergoing other psychopharmacological interventions
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the efficacy of Mahāpaiśacika Ghṛta in treating ADHD combined type?
How does Mahāpaiśacika Ghṛta compare to Kūṣmāṇḍa Ghṛta in ADHD treatment effectiveness and safety profiles?
Are there specific biomarkers that predict response to Ayurvedic formulations like Mahāpaiśacika Ghṛta in ADHD patients?
What are the potential adverse events associated with Mahāpaiśacika Ghṛta and Kūṣmāṇḍa Ghṛta in ADHD management?
What is the therapeutic landscape for Ayurvedic interventions in ADHD compared to conventional stimulant and non-stimulant drug classes?